MEDICAMEN BIOTECH CMP 516A long Weekly trendline breakout Looks amazing in charts
If sustaining above 530, New Target will be 626/727
Its a definitely a portfolio stock to be kept in holdings for double
MEDICAMEQ trade ideas
Medicamen Biotech LtdMedicamen Biotech Ltd
Incorporated in 1993, Medicamen Biotech Ltd is a research-led pharmaceutical company involved in developing, manufacturing, and marketing generic finished dosage formulations, and Oncology Formulations.
MBL, a subsidiary of Shivalik Rasayan Ltd with 41.6% ownership, is an integrated Pharmaceutical and Life Sciences Solution Provider. They manufacture pharmaceutical formulations, primarily focusing on oncology therapeutics and generics, distributed through wholesale drug distributors and sold to institutional segments such as government and semi-government institutions, and hospitals. Their formulations cover beta-lactam, non-beta-lactam, and cephalosporin drugs for overseas and domestic markets.
LONGW pattern , Double bottom pattern, its reversed after a long down trend. Likely targets given, strictly for long term.
risky trade in medicameqEmerging Tendulkar. Giving very good risk to reward. First target around 15%. Second 35%. Third 70%
Volatily contractionVolume dry-up; drifting sideways around 21 EMA.
Inside day candles.
RS higher; moved +6% where nifty tumbled by -2%.
EPS score of 91
RS rating 50
Pivot bought at 860.
SL 802
Publishing for my own reference. Not an investment/trading advise.
Medicamen Biotech------------ Long PlanMedicamen Biotech Ltd develops and markets a wide range of branded and generic formulations in the pharmaceutical industry.
KEY POINTS
Product Offerings
The company manufactures a wide range of formulations in the form of tablets, capsules, liquid syrup, dry syrup (beta lactum & non-beta lactum) ointment and Oral rehydration solution (ORS).
Therapeutic Areas
Its key therapeutic areas are antibiotic, antimalarial, antidiarrheal, antituberculosis & general pain management.
Geographical Presence
The company has geographical presence across India, S.E. Asia, Africa, Brazil, South Asia, CIS, Australia and others.
Entry into Oncology Business
The company entered into oncology area by establishing its 3rd manufacturing plant in FY21. The plant will manufacture oncology products such as tablets, capsules, injectables and lyophilizers. The facility is USFDA and EU compliant.
Manufacturing Capabilities
Presently, the company owns and operates 3 manufacturing facilities; 2 in Haridwar, Uttarakhand and 1 in Bhiwadi, Rajasthan. The facilities are certified by authorities like WHO, ANVISA (Brazil), NAFDAC, MCAZ, DACA, etc.
Upgradation of Facility - In Jan 2021, the company announced partial shutdown of its Bhiwadi facility for upgradation at 3 areas of the plant.
R&D Capabilities
It has a strength of ~45 R&D employees. It has spent ~20 crores towards R&D during FY18-20 and has filed 15 patents till FY20 with various authorities.
Acquisition of Opal Pharmaceuticals
During FY20, the company acquired OPAL Pharma; an Australian pharmaceutical company and medical supplies distributor. It was acquired for ~2.3 crores INR. (420,000 AUD).
Market Cap
₹ 1,200 Cr.
Current Price
₹ 982
High / Low
₹ 999 / 390
Stock P/E
77.3
Book Value
₹ 116
Dividend Yield
0.10 %
ROCE
12.7 %
ROE
9.73 %
Face Value
₹ 10.0
